The role of lymphoid organs in the pathogenesis of HIV infection

doi:10.1006/smim.1993.1019

Seminars in Immunology

Volume 5, Issue 3, June 1993, Pages 157-163

https://doi.org/10.1006/smim.1993.1019 Get rights and content

Abstract

Following primary human immunodeficiency virus (HIV) infection, HIV disease is characterized by a prolonged period, usually lasting several years, of clinical latency. During this period viremia is generally very low or undetectable, the number of infected cells (i.e. viral burden) in the blood are very low, and the levels of viral replication in these cells are barely detectable. These findings have been interpreted as a reflection of a phase of inactive HIV disease during which time HIV replicates very slowly or its replicating ability is kept under control by effective HIV specific immune responses. However, during this period a general deterioration of immune function and progressive depletion of CD4⁺ T cells occur; the inevitable outcome is clinically apparent disease. In the present article, we describe a model of disease development in which HIV infection is both active and progressive in the lymphoid organs during the clinically latent period of HIV infection when there are few, if any, signs of disease activity in peripheral blood.

References (0)

Cited by (53)

Single-cell RNA-seq analysis reveals dual sensing of HIV-1 in blood Axl<sup>+</sup> dendritic cells
2023, iScience
Sensing of incoming viruses is a pivotal task of dendritic cells (DCs). Human primary blood DCs encompass various subsets that are diverse in their susceptibility and response to HIV-1. The recent identification of the blood Axl⁺DC subset, endowed with unique capacities to bind, replicate, and transmit HIV-1 prompted us to evaluate its anti-viral response. We demonstrate that HIV-1 induced two main broad and intense transcriptional programs in different Axl⁺DCs potentially induced by different sensors; an NF-κB-mediated program that led to DC maturation and efficient CD4⁺ T cell activation, and a program mediated by STAT1/2 that activated type I IFN and ISG responses. These responses were absent from cDC2 exposed to HIV-1 except when viral replication was allowed. Finally, Axl⁺DCs actively replicating HIV-1 identified by quantification of viral transcripts exhibited a mixed NF-κB/ISG innate response. Our results suggest that the route of HIV-1 entry may dictate different innate sensing pathways by DCs.
Past, Present, and Future Drug Delivery Systems for Antiretrovirals
2016, Journal of Pharmaceutical Sciences
The human immunodeficiency virus has infected millions of people and the epidemic continues to grow rapidly in some parts of the world. Antiretroviral (ARV) therapy has provided improved treatment and prolonged the life expectancy of patients. Moreover, there is growing interest in using ARVs to protect against new infections. Hence, ARVs have emerged as our primary strategy in combating the virus. Unfortunately, several challenges limit the optimal performance of these drugs. First, ARVs often require life-long use and complex dosing regimens. This results in low patient adherence and periods of lapsed treatment manifesting in drug resistance. This has prompted the development of alternate dosage forms such as vaginal rings and long-acting injectables that stand to improve patient adherence. Another problem central to therapeutic failure is the inadequate penetration of drugs into infected tissues. This can lead to incomplete treatment, development of resistance, and viral rebound. Several strategies have been developed to improve drug penetration into these drug-free sanctuaries. These include encapsulation of drugs in nanoparticles, use of pharmacokinetic enhancers, and cell-based drug delivery platforms. In this review, we discuss issues surrounding ARV therapy and their impact on drug efficacy. We also describe various drug delivery–based approaches developed to overcome these issues.
The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche
2008, Seminars in Immunology
Citation Excerpt :
More than 90% of the first productively infected cells are a recently activated but ostensibly immunophenotypically ‘resting’ CD4+ T cells [47,48], and expansion of infection from small founder populations of these infected cells ‘broadcasts’ virus and infected cells, first to the draining lymph nodes and then systemically, in sufficient numbers to establish and maintain virus production in the lymphoid tissues throughout the host [47,48]. These secondary lymphatic tissues represent a reservoir of virus production and site of vast viral storage [49–55]. While ART can rapidly reduce the numbers of productively infected cells in LN within weeks [56], recent work suggests that suppression is not complete, because infected cells can still be found (albeit at a very low frequency) in LN and GALT of virtually all HIV-infected persons on ART, highlighting the importance of these sites as reservoirs of persistent viral replication [57,58].
The hallmark of HIV/SIV infections is the progressive depletion of CD4+ T cells that ultimately renders the host incapable of defending against AIDS defining opportunistic infections and malignancies. Although many potential mechanisms have been proposed to explain CD4+ T cell loss, we review here the growing evidence that fibrotic ‘scarring’ and consequent damage to the lymphatic tissue niche contributes to CD4+ T cell decline and limits CD4+ T cell re-population with retroviral therapy.
Psychobiology of HIV infection
2007, Psychoneuroimmunology, Two-Volume Set
Psychobiology of HIV Infection
2006, Psychoneuroimmunology
Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein
2005, Blood
Citation Excerpt :
However, heparan sulfate proteoglycans sequester and concentrate Tat at the cell surface,8,37 making it possible to obtain high local concentration of Tat both in vitro and in vivo (Figure 1 and Table 1). Moreover, in lymphoid tissue, viral load and Tat amounts go beyond by orders of magnitude than in bloodstream.47,48 Our results also indicate that Tat-mediated enhancement of LV-transduced cells is independent from its transactivating activity.
Human immunodeficiency virus-1 (HIV-1) Tat, a nuclear transactivator of viral gene expression, has the unusual property of being released by infected cells. Recent studies suggest that extracellular Tat is partially sequestered by heparan sulfate proteoglycans. As a consequence, Tat is concentrated on the cell surface and protected from proteolytic degradation, thus remaining in a biologically active form. We show that Tat binds the surfaces of both HIV-1–infected and surrounding uninfected cells. We provide evidence for a specific interaction between Tat and the HIV-1 glycoprotein 120 (gp120) envelope protein, which enhances virus attachment and entry into cells. We map the interacting sites of both Tat and gp120 and show that synthetic peptides mimicking the gp120 site inhibit HIV-1 infection. Our data demonstrate that membrane-associated Tat is a novel modulator of virus entry and suggest that the Tat-gp120 interaction represents a critical step in HIV-1 spreading during the course of infection.

View all citing articles on Scopus

View full text

Regular ArticleThe role of lymphoid organs in the pathogenesis of HIV infection

Abstract

Regular Article
The role of lymphoid organs in the pathogenesis of HIV infection